Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-03-03
2010-12-28
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S275000, C544S298000, C544S325000
Reexamination Certificate
active
07858632
ABSTRACT:
Compounds and methods for treating diseases mediated by a P2X3and/or a P2X2/3receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I):or a pharmaceutically acceptable salt, solvate or prodrug thereof,wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7and R8are as defined herein.
REFERENCES:
patent: 2657206 (1953-10-01), Hitchings et. al.
patent: 2953567 (1960-09-01), Burroughs
patent: 3715357 (1973-02-01), Rey-Bellet et al.
patent: 3849470 (1974-11-01), Cresswell et al.
patent: 3850927 (1974-11-01), Cresswell et al.
patent: 3852276 (1974-12-01), Cresswell et al.
patent: 3855265 (1974-12-01), Cresswell et al.
patent: 3878252 (1975-04-01), Cresswell et al.
patent: 3931181 (1976-01-01), Kompis et al.
patent: 3940393 (1976-02-01), Greenspan et al.
patent: 3991050 (1976-11-01), Cresswell et al.
patent: 4024145 (1977-05-01), Kompis
patent: 4033962 (1977-07-01), Rosen
patent: 4039543 (1977-08-01), Kompis et al.
patent: 4052553 (1977-10-01), Cresswell et al.
patent: 4075209 (1978-02-01), Jernow et al.
patent: 4108888 (1978-08-01), Rosen
patent: 4115650 (1978-09-01), Manchand
patent: 4143227 (1979-03-01), Rosen
patent: 4144263 (1979-03-01), Yeowell et al.
patent: 4151196 (1979-04-01), Rosen
patent: 4216319 (1980-08-01), Yeowell et al.
patent: 4232023 (1980-11-01), Dick et al.
patent: 4255574 (1981-03-01), Rosen
patent: 4258045 (1981-03-01), Poe et al.
patent: 4386084 (1983-05-01), Scharwaechter et al.
patent: 4415574 (1983-11-01), Laruelle et al.
patent: 4485248 (1984-11-01), Dall'Asta
patent: 4515948 (1985-05-01), Kompis et al.
patent: 4587341 (1986-05-01), Roth et al.
patent: 4590271 (1986-05-01), Daluge et al.
patent: 4883798 (1989-11-01), Petöcz et al.
patent: 4912112 (1990-03-01), Seydel et al.
patent: 4996198 (1991-02-01), Schildknecht et al.
patent: 5063219 (1991-11-01), Schildknecht et al.
patent: 5240640 (1993-08-01), Siiman et al.
patent: 5258373 (1993-11-01), Schildknecht et al.
patent: 5541186 (1996-07-01), Breu et al.
patent: 6136971 (2000-10-01), Harrington et al.
patent: 6211185 (2001-04-01), Strobel et al.
patent: 6410543 (2002-06-01), Strobel et al.
patent: 6423720 (2002-07-01), Gangjee
patent: 6440965 (2002-08-01), Kelley et al.
patent: 6583148 (2003-06-01), Kelley et al.
patent: 6916820 (2005-07-01), Kelley et al.
patent: 2003/0040513 (2003-02-01), Baxter et al.
patent: 0 237 516 (1987-09-01), None
patent: 0 658 548 (1997-11-01), None
patent: 0 959 073 (1999-11-01), None
patent: 0 743 307 (2001-09-01), None
patent: 0 959 072 (2002-09-01), None
patent: 1 310 493 (2003-05-01), None
patent: 9616963 (1996-06-01), None
patent: WO 01/17976 (2001-03-01), None
patent: WO 01/22938 (2001-04-01), None
patent: WO 01/81335 (2001-11-01), None
patent: WO 01/81338 (2001-11-01), None
patent: WO 02/08200 (2002-01-01), None
patent: WO 02/24665 (2002-03-01), None
patent: WO 02/053557 (2002-07-01), None
patent: WO 02/083650 (2002-10-01), None
patent: WO 02/094767 (2002-11-01), None
Caplus Abstract 98:179315 Michele Casas, et al.,Synthesis of new trimethoprim analogs. Antibacterial structure-activity relationship, Eur. J. Med. Chem, (1982), pp. 497-504, vol. 17(6).
Calas, M., et al, “Synthèses d-analogues nouveaus de la triméthoprime etude de relation structure-activité antibactérienne”, European Journal of Medicinal Chemistry, 1982, 17(6):497-504.
Dias Selassie, C., et al, “Quantitative structure-activity relationships of 2,4-diamino-5-(2-x-benzyl)pyrimidines versus bacterial and avian dihydrofolate reductase”, Journal of Medicinal Chemistry, 1998, 41:4261-4272.
Dunn, SMJ, et al, “Kinetics of ternary complex formation between dihydrofolate reductase, coenzyme, and inhibitors”,Biochemistry, 1980, 19:766-773.
Falco, Ea, et al, “5-Arylthiopyrimidines. I. 2,4-diamino derivatives”,Journal of Organic Chemistry, 1961, 26:1143-1146.
Seiler, P., et al “Partition coefficients of 5-(substituted benzyl)-2,4-diaminopyrimidines”,Arnzeim.-Forsch, 1982, 32(7):711-714.
Calas, M., et. al. “Synthese et antibacterienne de nouveaux analogues de la trimethoprime,” Annales Pharmaceutiques Francaises, 1985, vol. 43, No. 6, pp. 585-593.
Falco, E.A., et. al. “2,4-Diaminopyrimidines as Antimalarials. I. 5-Aryloxl and 5-Alkoxyl Derivatives,” Journal of the American Society, 1951, vol. 73, pp. 3753-3758.
Wei-Zhang Zhao, et. al., “Synthesis and Antibacterial Activity of 2,4-Diamino-5-(Substituted Anilino) Pyrimidines” Acta Pharmaceutica Sinica, 1987, vol. 22, No. 7, pp. 541-544.
Broka Chris Allen
Carter David Scott
Dillon Michael Patrick
Hawley Ronald Charles
Jahangir Alam
Hall Robert C.
Rao Deepak
Roche Palo Alto LLC
LandOfFree
Diaminopyrimidines as P2X 3 and P2X 2/3 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diaminopyrimidines as P2X 3 and P2X 2/3 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diaminopyrimidines as P2X 3 and P2X 2/3 antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4200805